Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06451263 · ClinicalTrials.gov registry record · NA
Nudge to Gynecologic Oncology
A NA study of Ovarian Cancer and Fallopian Tube Cancer, sponsored by Abramson Cancer Center at Penn Medicine.
- Active
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06451263: Active NA study of Ovarian Cancer and Fallopian Tube Cancer, sponsored by Abramson Cancer Center at Penn Medicine.
NCT06451263 is a NA study of Ovarian Cancer and Fallopian Tube Cancer that is active but no longer recruiting, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 20 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06451263, a NA study of Ovarian Cancer and Fallopian Tube Cancer, is active but no longer recruiting, sponsored by Abramson Cancer Center at Penn Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Ovarian cancer lacks an effective screening test, and prompt treatment at diagnosis is the only way to improve outcomes. Referral to gynecologic oncology at diagnosis of adnexal mass is recommend by guidelines from every major medical organization. Yet, 1 in 4 patients with ovarian cancer nationwide and at Penn Medicine never see a gynecologic oncologist. Even when referred to gynecologic oncology, patients from historically-marginalized groups have twice as long duration from diagnosis to seeing gynecologic oncology. In this project, the investigators will pilot a clinician nudge to gynecologic oncology referral and compare the impact to historical controls.
Primary Outcome
The primary implementation outcome is adoption, operationalized as the proportion of patients who are referred to gynecologic oncology within 30 days of diagnosis by study arm, to be evaluated overall and for historically marginalized patients.
Conditions Studied
Interventions
- BEHAVIORAL Nudge
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-01-19 |
| Est. Completion | 2027-05-31 |
| Phase | NA |
What the registry record for NCT06451263 still lists
NCT06451263 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (97% lower).
The record links to 3 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which Nudge is the first listed.
NCT06451263 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06451263 about?
NCT06451263 is a clinical study titled "Nudge to Gynecologic Oncology". Ovarian cancer lacks an effective screening test, and prompt treatment at diagnosis is the only way to improve outcomes. Referral to gynecologic oncology at diagnosis of adnexal mass is recommend by guidelines from every major medical organization. Yet, 1 in 4 patients with ovarian cancer nationwide...
What is the current status of trial NCT06451263?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2024-01-19. Estimated completion is 2027-05-31.
What conditions does trial NCT06451263 study?
This clinical trial studies the following conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer.
What interventions are being tested in trial NCT06451263?
The interventions under investigation include: Nudge (BEHAVIORAL).
Who is sponsoring clinical trial NCT06451263?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06451263 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06451263's enrollment target sits among peer trials
20 284th of 322 higher than 34 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian Cancer
RECRUITING · NA
-
ASk Questions in GYnecologic Oncology (ASQ-GYO)
RECRUITING · NA
-
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
RECRUITING · NA
-
Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women
RECRUITING · NA
-
REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors
RECRUITING · NA
-
Evaluating an Evidence-Based Family History Screening Program Adapted to Increase Reach and Uptake of Screening for BRCA-Associated Cancers in Rural Public Health Clinics
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI